Welcome to our dedicated page for EyePoint news (Ticker: EYPT), a resource for investors and traders seeking the latest updates and insights on EyePoint stock.
The EyePoint, Inc. (EYPT) news page on Stock Titan aggregates company-reported updates and market-moving announcements for this clinical-stage biopharmaceutical business focused on serious retinal diseases. EyePoint’s disclosures emphasize its lead investigational product, DURAVYU™ (vorolanib intravitreal insert), and its progress through late-stage clinical development, making corporate news particularly relevant for investors tracking ophthalmology and retinal therapeutics.
Visitors can review news covering clinical milestones, such as enrollment completion and data safety monitoring committee recommendations for the Phase 3 LUGANO and LUCIA trials in wet age-related macular degeneration (wet AMD), as well as the design and initiation of the pivotal Phase 3 COMO and CAPRI trials in diabetic macular edema (DME). Company releases also highlight Phase 2 data from the DAVIO 2 and VERONA studies, which EyePoint cites as demonstrating meaningful and sustained improvements in vision and anatomy with favorable safety profiles.
In addition to clinical trial updates, EyePoint’s news includes financing and corporate developments, such as underwritten public offerings, at-the-market equity programs, and inducement grants under Nasdaq Listing Rule 5635(c)(4). These items provide context on how the company funds its DURAVYU programs and earlier-stage pipeline initiatives. Investors can also follow announcements about conference presentations at major healthcare and ophthalmology meetings and investor conferences, where EyePoint discusses its clinical data, trial designs, and development strategy.
By monitoring the EYPT news feed, readers can see how EyePoint communicates progress on its investigational sustained-delivery approach, interactions with regulators, and key risk disclosures referenced in forward-looking statements. This page is useful for those who want a centralized view of EyePoint’s official announcements, ranging from clinical milestones and safety updates to capital-raising activities and corporate governance events.
EyePoint (Nasdaq: EYPT) provided a corporate update outlining pivotal 2026 milestones for DURAVYU (vorolanib intravitreal insert).
Key points: completed enrollment of >900 patients across Phase 3 LUGANO (432 U.S. patients) and LUCIA (475 global patients); topline wet AMD Phase 3 data expected beginning in mid-2026; Phase 3 DME trials COMO and CAPRI plan first patient dosing in Q1 2026 (~240 patients each); DURAVYU registration batches are in production to support an expedited NDA; corporate cash of approximately $300M at Dec 31, 2025 and a completed public offering raising $172.5M, providing runway into Q4 2027.
EyePoint (Nasdaq: EYPT) announced that Jay S. Duker, M.D., President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026 at 7:30 a.m. PT / 10:30 a.m. ET.
A live webcast and an archived replay will be available via the Investors section of the company website at www.eyepoint.bio.
EyePoint (Nasdaq: EYPT) granted inducement non‑statutory stock options to nine new employees on December 15, 2025 under Nasdaq Listing Rule 5635(c)(4).
The company awarded options to purchase an aggregate of 137,000 shares at an exercise price of $16.40 per share (closing price on December 15, 2025). Options have a 10‑year term and vest over 4 years: 25% on the first anniversary and the remainder in equal monthly installments over the following three years, subject to continued service. Grants were approved by the Compensation Committee.
EyePoint (Nasdaq: EYPT) announced a positive recommendation from an independent Data Safety Monitoring Committee (DSMC) after its second scheduled review of the pivotal Phase 3 LUGANO and LUCIA trials for DURAVYU in wet age-related macular degeneration (wet AMD) on Nov 19, 2025.
The DSMC found no safety signals and recommended both trials continue with no protocol changes. Enrollment is complete with over 900 patients. As of the Sept 29, 2025 cutoff all patients reached Week 8 and ~25% received a Week 32 redosing. Topline 56-week LUGANO data are on track for mid-2026, with LUCIA to closely follow.
EyePoint Pharmaceuticals (Nasdaq: EYPT) granted non-statutory stock options as inducement awards under NASDAQ Listing Rule 5635(c)(4) to seven new employees totaling 31,000 shares.
The options were granted on November 14, 2025, carry an exercise price of $11.58 (closing price that day), have a 10-year term, and vest over four years with 25% vesting at the first anniversary and the remainder monthly over three years, subject to continued service.
EyePoint (Nasdaq: EYPT) reported Q3 2025 results and corporate updates on Nov 5, 2025. Key operational items include completed enrollment of Phase 3 LUGANO and LUCIA for DURAVYU in wet AMD with >900 patients randomized and readouts beginning mid-2026, and initiation of a pivotal Phase 3 DME program (COMO and CAPRI) with first dosing expected Q1 2026 and FDA alignment on a non-inferiority approval pathway.
Preclinical data show DURAVYU reduces IL-6 activity >50% via JAK-1 inhibition plus VEGF receptor blockade. A $172.5 million underwritten offering in October fully funds the DME program and, with existing cash, extends runway into Q4 2027.
Q3 financials: revenue $1.0M versus $10.5M year-ago, operating expenses $63.0M, net loss $59.7M, and cash/securities $204M as of Sept 30, 2025 (plus ~$162M net October proceeds).
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced management will participate in three investor events in November 2025: a Guggenheim Healthcare Innovation fireside chat on Nov 10, 2025 at 10:30 a.m. ET, a Stifel 2025 Healthcare corporate presentation on Nov 12, 2025 at 10:40 a.m. ET, and Jefferies London investor 1x1 meetings on Nov 17, 2025.
A live webcast and archived replay of each presentation will be available via the Investors section of the company website at www.eyepointpharma.com.
EyePoint (NASDAQ: EYPT) will report its third quarter 2025 financial results on November 5, 2025 and will host a conference call and live webcast at 8:30 a.m. ET.
Investors can register for the live audio conference via the provided audio conference link and access a live audio webcast and replay through the company's Investors section at www.eyepointpharma.com.
EyePoint (NASDAQ: EYPT) granted inducement non‑statutory stock options to three new employees to purchase an aggregate of 13,500 shares, effective October 15, 2025, in accordance with NASDAQ Listing Rule 5635(c)(4).
The options carry an exercise price of $11.73 (closing price on October 15, 2025), a 10‑year term, and vest over four years (25% after one year, then monthly over three years), subject to continued service. Grants were approved by the Compensation Committee as inducements for new hires.
EyePoint (NASDAQ: EYPT) priced an underwritten public offering on Oct 14, 2025 of 11,000,000 common shares at $12.00 per share and pre-funded warrants to purchase up to 1,500,000 shares at $11.999 each.
The aggregate gross proceeds are expected to be approximately $150 million before underwriting discounts, with closing expected on or about Oct 16, 2025. EyePoint granted underwriters a 30-day option to purchase up to an additional 1,875,000 shares. Net proceeds are intended to fund clinical development of DURAVYU for wet AMD and DME, earlier-stage pipeline work, and general corporate purposes.
FAQ
What is the current stock price of EyePoint (EYPT)?
What is the market cap of EyePoint (EYPT)?
